Curis (CRIS) Competitors $1.29 0.00 (0.00%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.26 -0.03 (-1.94%) As of 04/15/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. DOMH, BOLT, SABS, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Dominari (DOMH), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Curis vs. Dominari Bolt Biotherapeutics SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Dominari (NASDAQ:DOMH) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do institutionals & insiders have more ownership in DOMH or CRIS? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 33.0% of Dominari shares are owned by company insiders. Comparatively, 5.7% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is DOMH or CRIS more profitable? Dominari has a net margin of -180.22% compared to Curis' net margin of -443.35%. Dominari's return on equity of -32.89% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Dominari-180.22% -32.89% -29.47% Curis -443.35%-923.37%-78.35% Do analysts recommend DOMH or CRIS? Curis has a consensus price target of $21.00, indicating a potential upside of 1,527.91%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Curis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, DOMH or CRIS? Dominari has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.51, meaning that its stock price is 251% more volatile than the S&P 500. Does the MarketBeat Community believe in DOMH or CRIS? Curis received 694 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformDominariN/AN/ACurisOutperform Votes69467.51% Underperform Votes33432.49% Which has preferable earnings and valuation, DOMH or CRIS? Dominari has higher revenue and earnings than Curis. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$12.59M3.42-$22.88M-$3.87-1.02Curis$10.91M1.00-$47.41M-$7.03-0.18 Does the media refer more to DOMH or CRIS? In the previous week, Curis had 1 more articles in the media than Dominari. MarketBeat recorded 4 mentions for Curis and 3 mentions for Dominari. Curis' average media sentiment score of 0.88 beat Dominari's score of 0.43 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Dominari Neutral Curis Positive SummaryDominari beats Curis on 9 of the 17 factors compared between the two stocks. Remove Ads Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.95M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-0.1730.9821.8117.82Price / Sales1.00440.40379.3794.59Price / CashN/A168.6838.1534.64Price / Book0.393.486.464.00Net Income-$47.41M-$72.06M$3.20B$247.23M7 Day Performance10.26%9.29%6.63%7.25%1 Month Performance-54.58%-17.01%-8.50%-6.24%1 Year Performance-91.14%-29.24%10.47%-0.17% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.3858 of 5 stars$1.29flat$21.00+1,527.9%-91.1%$10.95M$10.91M-0.1760Analyst ForecastDOMHDominari0.5461 of 5 stars$3.56-1.9%N/A+34.8%$38.85M$12.59M-0.924Earnings ReportShort Interest ↑Gap DownBOLTBolt Biotherapeutics2.7113 of 5 stars$0.35-2.4%$1.13+220.2%-69.5%$13.47M$7.69M-0.2190Short Interest ↑Gap DownSABSSAB Biotherapeutics3.5253 of 5 stars$1.11-1.8%$11.40+927.0%-68.5%$10.31M$2.24M-0.30140Short Interest ↓Gap DownMTEMMolecular TemplatesN/A$0.00-50.0%N/A-100.0%$1,000.00$23.48M0.00260Gap DownAMGNAmgen4.2689 of 5 stars$289.69-1.6%$314.04+8.4%+11.2%$155.62B$33.42B38.3728,000Analyst ForecastNews CoverageGILDGilead Sciences4.5365 of 5 stars$105.52-1.6%$105.12-0.4%+56.0%$131.39B$28.75B285.1917,000Positive NewsVRTXVertex Pharmaceuticals4.0995 of 5 stars$474.560.0%$509.17+7.3%+26.0%$121.86B$11.02B-215.716,100Short Interest ↓Analyst RevisionPositive NewsHigh Trading VolumeREGNRegeneron Pharmaceuticals4.8708 of 5 stars$572.78-0.1%$966.88+68.8%-37.9%$62.62B$14.20B14.9611,900Analyst ForecastPositive NewsHigh Trading VolumeALNYAlnylam Pharmaceuticals4.5644 of 5 stars$232.95-1.2%$316.25+35.8%+56.4%$30.30B$2.25B-107.352,000BIIBBiogen4.6938 of 5 stars$119.19-3.1%$213.33+79.0%-40.6%$17.45B$9.68B10.658,720Upcoming EarningsAnalyst Revision Remove Ads Related Companies and Tools Related Companies Dominari Competitors Bolt Biotherapeutics Competitors SAB Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRIS Stock Free CRIS Stock Alerts